Recent Finacing
Recent Raise
SynOx is a Dublin-based late clinical-stage biopharmaceutical developing emactuzumab, a CSF-1R–inhibiting monoclonal antibody for macrophage-driven disorders, conducting a global randomized double-blind placebo-controlled Phase 3 trial in TGCT.
